Ninlaro and Hepatic impairment
Result of checking the interaction of drug Ninlaro and disease Hepatic impairment for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Pharmacokinetic studies of ixazomib in patients with moderate to severe hepatic impairment, showed an increase AUC when compared to patients with normal hepatic function. The pharmacokinetic of ixazomib was similar in patients with normal hepatic function and in patients with mild hepatic impairment. It is recommended to reduce the starting dose in patients with moderate to severe hepatic impairment. Caution should be exercised when ixazomib is administered to patients with moderate to severe hepatic function and monitoring of liver function tests is recommended as appropriate.
Ninlaro - zaburzenia czynności wątroby 
Ninlaro - insuficiência hepática 
Ninlaro - gangguan hati 
Ninlaro - gangguan hati 
Ninlaro - insufficienza epatica 
Ninlaro - insuffisance hépatique 
Ninlaro - Leberfunktionsstörung 
Ninlaro - deterioro hepático 
Ninlaro - печеночная недостаточность 
Ninlaro - karaciğer yetmezliği 
Ninlaro - اختلال كبدي 
Ninlaro - 肝功能不全